Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
Company profile
Ticker
MRUS
Exchange
Website
CEO
Sven Lundberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merus B.V.
SEC CIK
MRUS stock data
Analyst ratings and price targets
Current price
Average target
$33.40
Low target
$28.00
High target
$39.00
EF Hutton
Initiated
$35.00
Citigroup
Maintains
$30.00
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
9 Jan 23
8-K
Departure of Directors or Certain Officers
6 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
31 May 22
10-Q
2022 Q1
Quarterly report
9 May 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
19 Apr 22
10-K
2021 FY
Annual report
28 Feb 22
8-K
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to
25 Jan 22
Latest ownership filings
SC 13G/A
FEDERATED HERMES, INC.
1 Feb 23
4
Peter B. Silverman
6 Jan 23
4
Harry Shuman
14 Dec 22
4
Harry Shuman
1 Dec 22
4
Sven Ante Lundberg
3 Nov 22
4/A
Sven Ante Lundberg
24 Oct 22
SC 13G
Flynn James E
30 Sep 22
4
Harry Shuman
29 Aug 22
4
Sven Ante Lundberg
23 Aug 22
4
Sven Ante Lundberg
22 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 192.13 mm | 192.13 mm | 192.13 mm | 192.13 mm | 192.13 mm | 192.13 mm |
| Cash burn (monthly) | 7.49 mm | (no burn) | 16.07 mm | 10.77 mm | 13.75 mm | 12.58 mm |
| Cash used (since last report) | 30.90 mm | n/a | 66.24 mm | 44.41 mm | 56.70 mm | 51.88 mm |
| Cash remaining | 161.23 mm | n/a | 125.89 mm | 147.72 mm | 135.43 mm | 140.25 mm |
| Runway (months of cash) | 21.5 | n/a | 7.8 | 13.7 | 9.8 | 11.1 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 101 |
| Opened positions | 18 |
| Closed positions | 12 |
| Increased positions | 38 |
| Reduced positions | 28 |
| 13F shares | Current |
|---|---|
| Total value | 1.04 bn |
| Total shares | 47.94 mm |
| Total puts | 15.90 k |
| Total calls | 0.00 |
| Total put/call ratio | Infinity |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 4.14 mm | $131.50 mm |
| FHI Federated Hermes | 3.60 mm | $72.06 mm |
| INCY Incyte | 3.55 mm | $99.97 mm |
| BVF | 3.44 mm | $68.99 mm |
| Commodore Capital | 2.62 mm | $52.39 mm |
| Deerfield Management | 2.52 mm | $50.51 mm |
| Flynn James E | 2.52 mm | $50.66 mm |
| Bay City Capital | 2.11 mm | $50.26 mm |
| Wellington Management | 1.94 mm | $38.81 mm |
| Boxer Capital | 1.90 mm | $38.06 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Jan 23 | Silverman Peter B. | Share Option(right to buy) Common Shares | Grant | Acquire A | No | No | 15.87 | 20,000 | 317.40 k | 20,000 |
| 13 Dec 22 | Harry Shuman | Common Shares | Sell | Dispose S | No | No | 13.85 | 168 | 2.33 k | 3,517 |
| 1 Dec 22 | Harry Shuman | Common Shares | Sell | Dispose S | No | Yes | 15.35 | 575 | 8.83 k | 3,685 |
| 1 Dec 22 | Harry Shuman | Common Shares | Option exercise | Acquire M | No | No | 0 | 2,500 | 0.00 | 4,260 |
| 1 Dec 22 | Harry Shuman | Restricted Share Unit Common Shares | Option exercise | Dispose M | No | No | 0 | 2,500 | 0.00 | 5,000 |
| 3 Nov 22 | Sven Ante Lundberg | Common Shares | Buy | Acquire P | No | Yes | 14.3772 | 14,706 | 211.43 k | 40,576 |
| 25 Aug 22 | Harry Shuman | Common Shares | Sell | Dispose S | No | No | 24.33 | 165 | 4.01 k | 1,760 |
News
Merus Announced Based On The Company's Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities, Expected To Fund Merus' Operations Into Second Half 2025
8 Jan 23
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
5 Jan 23
EF Hutton Initiates Coverage On Merus with Buy Rating, Announces Price Target of $35
5 Jan 23
Merus Earnings Perspective: Return On Capital Employed
24 Nov 22
5 Analysts Have This to Say About Merus
16 Nov 22